Reassessing Radioactive Iodine Use After Thyroidectomy in Low‐Risk Differentiated Thyroid Cancer: A Systematic Review and Meta‐Analysis
Endocrinology, Diabetes & Metabolism · 2026-09 · 9 (5)
DOI: 10.1002/edm2.70293 ↗At a glance
Systematische Übersicht in Endocrinology, Diabetes & Metabolism, published online on 2026-07-28. Written by Maheen Asif and 5 co-authors. Institution: Services Institute of Medical Sciences, Lahore, Pakistan. Major MEDLINE topics: Thyroid Neoplasms, Iodine Radioisotopes, Thyroidectomy. 29 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Radioactive iodine (RAI) therapy is often administered post‐total thyroidectomy in patients with low‐risk differentiated thyroid carcinoma, despite guidelines advising against its routine application. Evidence regarding the efficacy of RAI in reducing recurrence and improving survival in low‐risk differentiated thyroid cancer (DTC) remains inconsistent.
Methods
We conducted a systematic review and meta‐analysis of observational studies and randomized clinical trials that compare RAI versus no RAI in low‐risk DTC patients. Databases such as MEDLINE, Scopus, Cochrane Library, and Google Scholar were searched through December 2025. Outcomes included recurrence, recurrence‐free survival, treatment response, biochemical markers, and side effects. We performed statistical analysis using Review Manager (RevMan) 5.4 with a random‐effects model, reporting odds ratios (OR) with 95% confidence intervals, and significance set at p < 0.05. Heterogeneity was assessed using I 2 statistics.
Results
Ten studies ( n = 5260) were included in the analysis. No statistically significant difference was observed between the two groups for recurrence (OR 0.66, 95% CI: 0.41–1.08; p = 0.10), 5‐year recurrence‐free survival (OR 2.47, 95% CI: 0.63–9.62; p = 0.19), or treatment response (excellent response: OR 1.00, 95% CI: 0.52–1.92; p = 1.00). Secondary outcomes, including serum thyroglobulin > 1 ng/mL (OR 1.20, 95% CI: 0.00–342.55; p = 0.95), elevated thyroglobulin antibodies (OR 0.91, 95% CI: 0.38–2.16; p = 0.83), xerostomia (OR 5.63, 95% CI: 0.05–667.24; p = 0.48), and dysphonia (OR 0.96, 95% CI: 0.53–1.72; p = 0.88), were also not significantly different between groups, although estimates were not precise.
Conclusion
The available randomized and observational evidence does not demonstrate a clear, clinically meaningful benefit of routine RAI ablation in patients classified as low‐risk DTC. These findings should be interpreted with caution due to heterogeneity across studies, variability in outcome definitions, and the predominance of observational data.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Services Institute of Medical Sciences, Lahore, Pakistan.
- King Edward Medical University, Lahore, Pakistan.
- Alzaiem Alazhari University, Khartoum, Sudan.
ORCID profiles: Maheen Asif, Mudasar Nisar, Aliza Asif, Makzooma Batool, Rabia Javed Iqbal
Cite
APA
Asif, M., Nisar, M., Asif, A., Batool, M., Iqbal, R. J., & Amin, M. H. J. (2026). Reassessing Radioactive Iodine Use After Thyroidectomy in Low‐Risk Differentiated Thyroid Cancer: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism, 9(5). https://doi.org/10.1002/edm2.70293
Vancouver
Asif M, Nisar M, Asif A, Batool M, Iqbal RJ, Amin MHJ. Reassessing Radioactive Iodine Use After Thyroidectomy in Low‐Risk Differentiated Thyroid Cancer: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism. 2026;9(5). doi:10.1002/edm2.70293
BibTeX
@article{Asif2026,
author = {Asif, Maheen and Nisar, Mudasar and Asif, Aliza and Batool, Makzooma and Iqbal, Rabia Javed and Amin, Mohammed Hammad Jaber},
title = {Reassessing Radioactive Iodine Use After Thyroidectomy in Low‐Risk Differentiated Thyroid Cancer: A Systematic Review and Meta‐Analysis},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
volume = {9},
number = {5},
doi = {10.1002/edm2.70293}
}
EUVIMED